Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Collegium Pharmaceutical Inc (COLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: COLL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.6
1 Year Target Price $44.6
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.55% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.12B USD | Price to earnings Ratio 33.53 | 1Y Target Price 44.6 |
Price to earnings Ratio 33.53 | 1Y Target Price 44.6 | ||
Volume (30-day avg) 5 | Beta 0.65 | 52 Weeks Range 23.23 - 39.95 | Updated Date 10/24/2025 |
52 Weeks Range 23.23 - 39.95 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.13% | Operating Margin (TTM) 20.02% |
Management Effectiveness
Return on Assets (TTM) 7.76% | Return on Equity (TTM) 16.16% |
Valuation
Trailing PE 33.53 | Forward PE 4.79 | Enterprise Value 1686849913 | Price to Sales(TTM) 1.58 |
Enterprise Value 1686849913 | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 2.39 | Enterprise Value to EBITDA 4.87 | Shares Outstanding 31502127 | Shares Floating 28098322 |
Shares Outstanding 31502127 | Shares Floating 28098322 | ||
Percent Insiders 1.72 | Percent Institutions 116.25 |
Upturn AI SWOT
Collegium Pharmaceutical Inc
Company Overview
History and Background
Collegium Pharmaceutical, Inc. was founded in 2003. It initially focused on developing abuse-deterrent opioid products. Over time, it evolved to include a broader portfolio of pain management solutions.
Core Business Areas
- Pain Management: Develops, manufactures, and commercializes pain management medications with a focus on products designed to deter abuse.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives. The company operates with a structure designed to support research, development, manufacturing, and commercialization activities. Exact leadership changes regularly and should be verified with the latest available information.
Top Products and Market Share
Key Offerings
- Xtampza ER: Xtampza ER is an abuse-deterrent extended-release oxycodone formulation. Exact market share data varies, but it competes with other extended-release opioid pain relievers. Key competitors include Purdue Pharma (OxyContin), and generic extended-release oxycodone products.
- Nucynta ER/IR: Nucynta ER/IR (tapentadol) is a pain medication. Exact market share data is variable. Competitors include tramadol and other centrally acting analgesics.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. Demand for pain management solutions remains strong, but there's increasing pressure to address opioid abuse and addiction.
Positioning
Collegium Pharmaceutical Inc. focuses on abuse-deterrent opioid formulations and non-opioid pain management options to differentiate itself in the market. Their competitive advantage relies on intellectual property and regulatory approvals for these products.
Total Addressable Market (TAM)
The TAM for pain management is substantial, estimated at billions of dollars annually. Collegium's positioning with abuse-deterrent and non-opioid options aims to capture a significant share of this market while addressing concerns about opioid abuse.
Upturn SWOT Analysis
Strengths
- Abuse-deterrent technology
- Established product portfolio in pain management
- Experienced management team
- Focus on innovation
Weaknesses
- Reliance on opioid products
- Exposure to opioid-related litigation and regulatory scrutiny
- Limited product diversification
- High marketing and sales expenses
Opportunities
- Development of non-opioid pain management therapies
- Expansion into new markets
- Partnerships and acquisitions
- Increased awareness of abuse-deterrent formulations
Threats
- Generic competition
- Stringent regulatory environment
- Opioid crisis and related lawsuits
- Changing prescribing practices
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- PRGO
- ENDP
Competitive Landscape
Collegium's advantage lies in abuse-deterrent technology. However, they face competition from generic manufacturers and larger pharmaceutical companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been influenced by product launches, acquisitions, and market trends in pain management.
Future Projections: Future growth projections are based on analyst estimates and depend on factors like product pipeline, regulatory approvals, and market demand. Analyst reports can be found on financial websites.
Recent Initiatives: Recent strategic initiatives include product development, partnerships, and market expansion efforts. Specific details can be found in company press releases and investor presentations.
Summary
Collegium Pharmaceutical focuses on pain management, particularly abuse-deterrent opioids. While abuse-deterrent technology is a strength, opioid-related risks persist. They face competition from generics and larger companies. Future growth depends on developing non-opioid alternatives and managing regulatory pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial websites
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and financial information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collegium Pharmaceutical Inc
Exchange NASDAQ | Headquaters Stoughton, MA, United States | ||
IPO Launch date 2015-05-07 | CEO, President, Executive VP & Director Mr. Vikram Karnani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 357 | Website https://www.collegiumpharma.com |
Full time employees 357 | Website https://www.collegiumpharma.com | ||
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.